A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants

A Phase 1 Study to Evaluate the Pharmacokinetics of LY2605541 Injection and Insulin Lispro Injection Administered as Mixture or as Individual Components in Healthy Subjects

The main purpose of this study is to evaluate how the body absorbs and removes LY2605541, insulin lispro, and a mixture of both from the blood. The study has two parts. Participants may enroll in only one part. Each part has four treatment periods in a fixed order. The study will last approximately 8 weeks, not including screening. Screening is required within 28 days prior to the start of the study.

Inclusion Criteria:

• Are not of child-bearing potential
• Have a body mass index (BMI) between 18 and 29.9 kilograms per meter squared (kg/m^2), inclusive
• Are nonsmokers or have not smoked for at least 2 months prior to entering the study

Exclusion Criteria:

• Have known allergies to insulin or its excipients, or related drugs, or history of relevant allergic reactions of any origin
• Have a history of first-degree relatives known to have diabetes mellitus
• Have used systemic glucocorticoids within 3 months prior to entry into the study
• Have donated blood or had a blood loss of 450 milliliter (mL) within 1 month prior to study enrollment